Patents Assigned to Monogram Biosciences, Inc.
-
Publication number: 20230313327Abstract: The invention provides a method for determining whether a human immunodeficiency virus is resistant to a viral entry inhibitor. The methods are particularly useful for determining resistance to inhibitors that act by a non-competitive mechanism. In certain aspects, the methods comprise determining whether an HIV population is resistant to an HIV entry inhibitor, comprising determining a log-sigmoid inhibition curve comprising data points for entry of the HIV population in the presence of varying concentrations of the HIV entry inhibitor, wherein if the entry of the HIV population cannot be completely inhibited by the HIV entry inhibitor, the HIV population is resistant to the HIV entry inhibitor.Type: ApplicationFiled: October 3, 2022Publication date: October 5, 2023Applicant: Monogram Biosciences, Inc.Inventor: Christos J. Petropoulos
-
Patent number: 11499200Abstract: The invention provides a method for treating a patient having human immunodeficiency virus (HIV) infection by determining whether the human immunodeficiency virus is likely to be more resistant to a viral entry inhibitor than a reference HIV and treating the patient based on that determination. In certain aspects, the methods comprise detecting whether the envelope protein from an HIV from the patient comprises a mutation or mutations in codons 117, 421, 121, and/or 298, wherein the presence of the mutation or mutations indicates that the HIV is likely to be more susceptible to the entry inhibitor than the reference HIV.Type: GrantFiled: August 19, 2019Date of Patent: November 15, 2022Assignee: Monogram Biosciences, Inc.Inventor: Wei Huang
-
Patent number: 11459624Abstract: The invention provides a method for determining whether a human immunodeficiency virus is resistant to a viral entry inhibitor. The methods are particularly useful for determining resistance to inhibitors that act by a non-competitive mechanism. In certain aspects, the methods comprise determining whether an HIV population is resistant to an HIV entry inhibitor, comprising determining a log-sigmoid inhibition curve comprising data points for entry of the HIV population in the presence of varying concentrations of the HIV entry inhibitor, wherein if the entry of the HIV population cannot be completely inhibited by the HIV entry inhibitor, the HIV population is resistant to the HIV entry inhibitor.Type: GrantFiled: February 3, 2020Date of Patent: October 4, 2022Assignee: Monogram Biosciences, Inc.Inventor: Christos J. Petropoulos
-
Publication number: 20200332373Abstract: The invention provides a method for determining whether a human immunodeficiency virus is resistant to a viral entry inhibitor. The methods are particularly useful for determining resistance to inhibitors that act by a non-competitive mechanism. In certain aspects, the methods comprise determining whether an HIV population is resistant to an HIV entry inhibitor, comprising determining a log-sigmoid inhibition curve comprising data points for entry of the HIV population in the presence of varying concentrations of the HIV entry inhibitor, wherein if the entry of the HIV population cannot be completely inhibited by the HIV entry inhibitor, the HIV population is resistant to the HIV entry inhibitor.Type: ApplicationFiled: February 3, 2020Publication date: October 22, 2020Applicant: Monogram Biosciences, Inc.Inventor: Christos J. Petropoulos
-
Publication number: 20200216919Abstract: The invention provides a method for determining whether a human immunodeficiency virus is likely to be more resistant to a viral entry inhibitor than a reference HIV. In certain aspects, the methods comprise comparing the length of one or more variable regions of an envelope protein of the HIV or a number of glycosylation sites on the envelope protein of the HIV to a length of one or more corresponding variable regions of an envelope protein of the reference HIV or a number of glycosylation sites on the envelope protein of the reference HIV, wherein the HIV is likely to be more resistant to the CD4 binding site entry inhibitor than the reference HIV when the HIV has longer variable regions than the reference HIV or the HIV has more glycosylation sites than the reference HIV.Type: ApplicationFiled: August 19, 2019Publication date: July 9, 2020Applicant: Monogram Biosciences, Inc.Inventor: Wei Huang
-
Patent number: 10550441Abstract: The invention provides a method for determining whether a human immunodeficiency virus is resistance to a viral entry inhibitor. The methods are particularly useful for determining resistance to inhibitors that act by a non-competitive mechanism. In certain aspects, the methods comprise determining whether an HIV population is resistant to an HIV entry inhibitor, comprising determining a log-sigmoid inhibition curve comprising data points for entry of the HIV population in the presence of varying concentrations of the HIV entry inhibitor, wherein if the entry of the HIV population cannot be completely inhibited by the HIV entry inhibitor, the HIV population is resistant to the HIV entry inhibitor.Type: GrantFiled: December 9, 2013Date of Patent: February 4, 2020Assignee: Monogram BioSciences, Inc.Inventor: Christos J. Petropoulos
-
Patent number: 10416162Abstract: In certain aspects, the present invention provides methods for determining whether a Her-2 positive cancer is likely to respond to treatment with a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a slow disease progression. In other aspects, the present invention is drawn to methods for determining whether a subject with a Her-2 positive cancer is unlikely to respond to treatment with at least one chemotherapeutic agent in addition to a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a fast disease progression.Type: GrantFiled: December 19, 2008Date of Patent: September 17, 2019Assignee: Monogram Biosciences, Inc.Inventors: Weidong Huang, Jeff Sperinde, Michael Bates, Colombe Chappey, John William Winslow
-
Patent number: 10385411Abstract: The invention provides a method for determining whether a human immunodeficiency virus is likely to be more resistant to a viral entry inhibitor than a reference HIV. In certain aspects, the methods comprise comparing the length of one or more variable regions of an envelope protein of the HIV or a number of glycosylation sites on the envelope protein of the HIV to a length of one or more corresponding variable regions of an envelope protein of the reference HIV or a number of glycosylation sites on the envelope protein of the reference HIV, wherein the HIV is likely to be more resistant to the CD4 binding site entry inhibitor than the reference HIV when the HIV has longer variable regions than the reference HIV or the HIV has more glycosylation sites than the reference HIV.Type: GrantFiled: November 28, 2016Date of Patent: August 20, 2019Assignee: Monogram BioSciences, Inc.Inventor: Wei Huang
-
Patent number: 10202658Abstract: This invention relates to methods for determining hypersusceptibility of HIV-1 viruses to non-nucleoside reverse transcriptase inhibitors (NNRTIs) based on the viral genotypes. The methods generally comprise detecting, in a gene encoding reverse transcriptase of the HIV-1, the presence of a mutation at codon 65, 69, or 74 alone or in combination with one or more mutations at certain other codons. Combinations of mutations associated with hypersusceptibility to NNRTIs are also disclosed.Type: GrantFiled: May 9, 2012Date of Patent: February 12, 2019Assignee: Monogram Biosciences, Inc.Inventors: Neil T. Parkin, Eoin Coakley
-
Publication number: 20190025305Abstract: The present invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal producedType: ApplicationFiled: December 11, 2017Publication date: January 24, 2019Applicant: Monogram Biosciences, Inc.Inventors: Douglas Richman, Mary T. Wrin, Susan Little, Christos J. Petropoulos, Neil T. Parkin, Jeannette Whitcomb, Wei Huang
-
Patent number: 10161931Abstract: The invention provides a method for determining whether a human immunodeficiency virus is likely to be have enhanced ability to enter a cell expressing CD4 and CXCR4 relative to a reference HIV. In certain aspects, the methods comprise detecting one or more amino acids in an envelope protein of the HIV associated with enhanced ability to enter CD4- and CXCR4-expressing cells and determining that the HIV's ability to enter such cells is enhanced relative to a reference HIV, e.g., an HIV that does not comprise such amino acid(s).Type: GrantFiled: November 10, 2016Date of Patent: December 25, 2018Assignee: Monogram Biosciences, Inc.Inventor: Wei Huang
-
Patent number: 9939447Abstract: Compositions, kits, and methods are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. The compositions can include a first reagent including a cleavage-inducing moiety and a first binding agent for a binding site that includes a post-translational modification of a target polypeptide.Type: GrantFiled: August 14, 2015Date of Patent: April 10, 2018Assignee: Monogram Biosciences, Inc.Inventors: Sharat Singh, Hossein Salimi-Moosavi, Syed Hasan Tahir, Gerald J. Wallweber, Hrair Kirakossian, Tracy J. Matray, Vincent S. Hernandez
-
Patent number: 9841425Abstract: Provided are methods for identifying whether a compound inhibits entry of a virus into a cell. The method may include obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus and co-transfecting it into a first cell along with a viral expression vector which lacks a nucleic acid encoding the envelope protein. The method may further include contacting the viral particles produced by the first cell with a second cell to which the virus binds in the absence and presence of the compound and measuring the amount of signal produced by the second cell.Type: GrantFiled: October 29, 2015Date of Patent: December 12, 2017Assignee: Monogram Biosciences, Inc.Inventors: Douglas Richman, Mary T Wrin, Susan Little, Christos J. Petropoulos, Neil T. Parkin, Jeannette Whitcomb, Wei Huang
-
Publication number: 20170145523Abstract: The invention provides a method for determining whether a human immunodeficiency virus is likely to be more resistant to a viral entry inhibitor than a reference HIV. In certain aspects, the methods comprise comparing the length of one or more variable regions of an envelope protein of the HIV or a number of glycosylation sites on the envelope protein of the HIV to a length of one or more corresponding variable regions of an envelope protein of the reference HIV or a number of glycosylation sites on the envelope protein of the reference HIV, wherein the HIV is likely to be more resistant to the CD4 binding site entry inhibitor than the reference HIV when the HIV has longer variable regions than the reference HIV or the HIV has more glycosylation sites than the reference HIV.Type: ApplicationFiled: November 28, 2016Publication date: May 25, 2017Applicant: Monogram Biosciences, Inc.Inventor: Wei Huang
-
Publication number: 20170067878Abstract: The invention provides a method for determining whether a human immunodeficiency virus is likely to be have enhanced ability to enter a cell expressing CD4 and CXCR4 relative to a reference HIV. In certain aspects, the methods comprise detecting one or more amino acids in an envelope protein of the HIV associated with enhanced ability to enter CD4- and CXCR4-expressing cells and determining that the HIV's ability to enter such cells is enhanced relative to a reference HIV, e.g., an HIV that does not comprise such amino acid(s).Type: ApplicationFiled: November 10, 2016Publication date: March 9, 2017Applicant: Monogram Biosciences, Inc.Inventor: Wei Huang
-
Patent number: 9506121Abstract: The invention provides a method for determining whether a human immunodeficiency virus is likely to be more resistant to a viral entry inhibitor than a reference HIV. In certain aspects, the methods comprise comparing the length of one or more variable regions of an envelope protein of the HIV or a number of glycosylation sites on the envelope protein of the HIV to a length of one or more corresponding variable regions of an envelope protein of the reference HIV or a number of glycosylation sites on the envelope protein of the reference HIV, wherein the HIV is likely to be more resistant to the CD4 binding site entry inhibitor than the reference HIV when the HIV has longer variable regions than the reference HIV or the HIV has more glycosylation sites than the reference HIV.Type: GrantFiled: June 6, 2006Date of Patent: November 29, 2016Assignee: MONOGRAM BIOSCIENCES, INC.Inventor: Wei Huang
-
Patent number: 9493847Abstract: The invention provides a method for determining whether a human immunodeficiency virus is likely to be have enhanced ability to enter a cell expressing CD4 and CXCR4 relative to a reference HIV. In certain aspects, the methods comprise detecting one or more amino acids in an envelope protein of the HIV associated with enhanced ability to enter CD4- and CXCR4-expressing cells and determining that the HIV's ability to enter such cells is enhanced relative to a reference HIV, e.g., an HIV that does not comprise such amino acid(s).Type: GrantFiled: February 9, 2012Date of Patent: November 15, 2016Assignee: MONOGRAM BIOSCIENCES, INC.Inventor: Wei Huang
-
Publication number: 20160069893Abstract: Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. A mixture comprising the sample and a first reagent comprising a cleavage-inducing moiety and a first binding agent for a binding site on a target polypeptide is subjected to conditions under which binding of respective binding moieties occurs. The binding site is the result of post-translational modification activity involving the target polypeptide. The method may be employed to determine the target polypeptide itself. In another embodiment the presence and/or amount of the target polypeptide is related to the presence and/or amount and/or activity of an agent such as an enzyme involved in the post-translational modification of the target polypeptide.Type: ApplicationFiled: August 14, 2015Publication date: March 10, 2016Applicant: MONOGRAM BIOSCIENCES, INC.Inventors: Sharat Singh, Hossein Salimi-Moosavi, Syed Hasan Tahir, Gerald J. Wallweber, Hrair Kirakossian, Tracy J. Matray, Vincent S. Hernandez
-
Patent number: 9175355Abstract: The present invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal producedType: GrantFiled: December 10, 2009Date of Patent: November 3, 2015Assignee: Monogram Biosciences, Inc.Inventors: Douglas Richman, Mary T. Wrin, Susan Little, Christos J. Petropoulos, Neil T. Parkin, Jeannette Whitcomb, Wei Huang
-
Patent number: 9110075Abstract: Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification.Type: GrantFiled: October 4, 2011Date of Patent: August 18, 2015Assignee: Monogram Biosciences, Inc.Inventors: Sharat Singh, Hossein Salimi-Moosavi, Syed Hasan Tahir, Gerald J. Wallweber, Hrair Kirakossian, Tracy J. Matray, Vincent S. Hernandez